International Journal of Stem Cells : eISSN 2005-5447

Fig. 5.

Download original image
Fig. 5. Drug cytotoxicity analysis of sirolimus, leflunomide, and teriflunomide evaluated by MTT Tetrazolium Assay (I) and Resazurin Reduction Assay (CellTiter-Blue Cell Viability Assay) (II). Cyclosporin was not cytotoxic for both cell types in the analyzed doses, however, showed a reduction of cell viability greater than 50% for hES-RPE at the dose of 100 μM. Sirolimus (IB and IIB) showed higher cytotoxicity than leflunomide and its active metabolite, teriflunomide. TAC treatment (IC and IIC) showed cytotoxic for ARPE-19 at dose evaluated 100 μM (102) while it was cytotoxic for hES-ARPE at dose evaluated 176 μM (102.25). Leflunomide treatment (ID and IID) was cytotoxic for ARPE-19 at the highest dose evaluated (178 μM, 102.25) while it was not cytotoxic for hES-ARPE cells at this concentration. Teriflunomide treatment (IE and IIE), however, showed cytotoxicity for both cell types with the dose of 178 μM (102.25), and at 100 μM (102) ARPE-19 cells were also susceptible, but not hES-RPE cells. *significant difference comparing hES-RPE control and hES-RPE treatments; #significant difference comparing ARPE-19 control and ARPE-19 treatments; +significant difference comparing hES-RPE and ARPE-19 at same concentration.
International Journal of Stem Cells 2021;14:74-84
© 2020 International Journal of Stem Cells